Semaglutide Pen Injector [Ozempic] for Diabetes

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Diabetes+1 MoreSemaglutide Pen Injector [Ozempic] - Drug
Eligibility
18 - 89
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking for genetic variants associated with the effects of a GLP1R agonist on insulin secretion and glucose metabolism in overweight/obese, otherwise healthy Amish volunteers.

Eligible Conditions
  • Diabetes
  • Obesity

Treatment Effectiveness

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: Assessed after completing 6 weeks of semaglutide therapy

Week 6
Weight loss
Week 6
Insulin
Glucose effectiveness (Sg)
Insulin sensitivity (Si)
Rate of glucose disappearance
Second phase insulin secretion

Trial Safety

Trial Design

1 Treatment Group

Open label administration of semaglutide
1 of 1

Experimental Treatment

600 Total Participants · 1 Treatment Group

Primary Treatment: Semaglutide Pen Injector [Ozempic] · No Placebo Group · Phase 1

Open label administration of semaglutide
Drug
Experimental Group · 1 Intervention: Semaglutide Pen Injector [Ozempic] · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: assessed after completing 6 weeks of semaglutide therapy

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
610 Previous Clinical Trials
333,205 Total Patients Enrolled
3 Trials studying Diabetes
3,990 Patients Enrolled for Diabetes
Amber L Beitelshees, PharmDPrincipal InvestigatorUniversity of Maryland, Baltimore

Eligibility Criteria

Age 18 - 89 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a body mass index (BMI) greater than or equal to 27 kg/m2.

Who else is applying?

What state do they live in?
Illinois50.0%
Ohio50.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Amish Research Clinic100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria50.0%
Met criteria50.0%
Why did patients apply to this trial?
  • "I want to lose weight but can't afford medicine"
How many prior treatments have patients received?
1100.0%